Dr. William Williams reports

BRIACELL COMPLETES MANUFACTURING OF CLINICAL SUPPLIES OF BRIA-PROS+ FOR PROSTATE CANCER

Briacell Therapeutics Corp. has completed manufacturing clinical supplies of Bria-PROS+, its next-generation, personalized, off-the-shelf, cell-based immunotherapy candidate for prostate cancer.

In August, 2025, Briacell was awarded a $2-million non-dilutive grant from the U.S. National Cancer Institute to support the manufacturing and planned clinical evaluation of Bria-PROS+.

"We are pleased to announce the completion of clinical supply manufacturing for Bria-PROS+, our next-generation personalized immunotherapy candidate for prostate cancer," stated Dr. William V. Williams, Briacell's president and chief executive officer. "The design of Bria-PROS+ is intended to support enhanced immune system activation while maintaining a favourable safety profile. We look forward to advancing Bria-PROS+ into the clinic as we seek to develop new treatment options for prostate cancer patients who do not respond to available therapies."

As reported in Briacell's recent AACR preclinical poster presentation, Bria-PROS+ demonstrated activation of both adaptive and innate immunity, including activation of naive (resting) T-cells, dendritic cells and natural killer cells. Briacell believes these preclinical findings support further clinical evaluation as a potential immunotherapy for prostate cancer. Bria-PROS+ is based on the same Bria-OTS+ platform as Bria-BRES+, Briacell's next-generation breast cancer immunotherapy candidate, which recently received Food and Drug Administration clearance of its investigational new drug application.

Bria-PROS+ builds on Bria-Cell's Bria-OTS clinical program in breast cancer, where the first patient dosed experienced the sustained complete resolution of a lung metastasis. This 78-year-old woman with advanced metastatic breast cancer and multiple prior treatment failures achieved complete (100 per cent) resolution of a lung metastasis following four doses of Bria-OTS single agent therapy. The complete response of the lesion, initially observed at two months, was subsequently confirmed at four months, six months and at 11 months. The patient received 17 cycles of Bria-OTS, completed 12 months of the study, and remains in survival follow-up.

About Briacell Therapeutics Corp.

Briacell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer.

We seek Safe Harbor.